This is how Novavax reliably protects against corona diseases

This study gives hope: The efficacy against “mild, moderate and severe diseases caused by the original Covid-19 strain” is 96.4 percent, Novavax said. This means: 96.4 percent fewer illnesses occurred among the test subjects in the vaccinated group than among those in the control group.

British Health Secretary Matt Hancock spoke of “really encouraging results”. Britain ordered 60 million doses of the vaccine. Hancock noted on Friday that these cans are made in the northeast of England.